Indofarma Tbk (JK:INAF) — Stock Price
Indofarma Tbk (JK:INAF) is currently trading at Rp126.00 IDR, up 0.00% today. Over the past 52 weeks, shares have ranged between Rp126.00 and Rp126.00. This page tracks Indofarma Tbk's live share price on the JK exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see INAF market cap overview.
Indofarma Tbk (INAF) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Indofarma Tbk's daily closing share price and trading volume on the JK exchange over the past year, giving a clear view of recent price momentum and liquidity.
Indofarma Tbk Income Statement — Revenue, Profit & Earnings by Year
Indofarma Tbk's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Rp210.38 Billion | Rp523.60 Billion | Rp1.14 Trillion | Rp2.90 Trillion | Rp1.72 Trillion |
| Cost of Revenue | Rp247.89 Billion | Rp695.56 Billion | Rp1.25 Trillion | Rp2.45 Trillion | Rp1.31 Trillion |
| Gross Profit | Rp-37.51 Billion | Rp-171.96 Billion | Rp-110.11 Billion | Rp451.65 Billion | Rp400.60 Billion |
| Research & Development | — | Rp592.43 Million | Rp552.77 Million | Rp763.95 Million | Rp501.24 Million |
| SG&A | Rp67.03 Billion | Rp115.82 Billion | Rp42.94 Billion | Rp45.75 Billion | Rp41.16 Billion |
| Total Operating Expenses | Rp216.22 Billion | Rp439.18 Billion | Rp338.25 Billion | Rp394.89 Billion | Rp298.35 Billion |
| Operating Income | Rp-253.73 Billion | Rp-603.46 Billion | Rp-479.54 Billion | Rp51.98 Billion | Rp87.66 Billion |
| EBITDA | Rp-246.54 Billion | Rp-581.38 Billion | Rp-479.11 Billion | Rp86.68 Billion | Rp86.76 Billion |
| EBIT | Rp-253.74 Billion | Rp-609.02 Billion | Rp-511.24 Billion | Rp52.08 Billion | Rp58.49 Billion |
| Interest Expense | Rp30.01 Billion | Rp60.49 Billion | Rp38.08 Billion | Rp42.96 Billion | Rp38.25 Billion |
| Income Before Tax | Rp-283.76 Billion | Rp-669.51 Billion | Rp-517.56 Billion | Rp8.77 Billion | Rp18.08 Billion |
| Income Tax Expense | Rp50.73 Billion | Rp51.49 Billion | Rp-89.07 Billion | Rp46.34 Billion | Rp18.05 Billion |
| Net Income | Rp-334.49 Billion | Rp-720.99 Billion | Rp-428.49 Billion | Rp-37.57 Billion | Rp27.58 Million |
Indofarma Tbk Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Indofarma Tbk's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Rp618.16 Billion | Rp759.83 Billion | Rp1.53 Trillion | Rp2.01 Trillion | Rp1.71 Trillion |
| Total Current Assets | Rp134.19 Billion | Rp198.99 Billion | Rp863.58 Billion | Rp1.41 Trillion | Rp1.13 Trillion |
| Cash & Equivalents | — | — | Rp268.44 Billion | Rp342.34 Billion | Rp97.05 Billion |
| Short-term Investments | — | — | Rp39.00 Billion | Rp35.00 Billion | Rp-13.40 Billion |
| Net Receivables | Rp46.92 Billion | Rp65.70 Billion | Rp301.27 Billion | Rp648.93 Billion | Rp571.80 Billion |
| Inventory | Rp33.33 Billion | Rp65.93 Billion | Rp243.97 Billion | Rp333.73 Billion | Rp144.77 Billion |
| Property, Plant & Equipment | Rp383.13 Billion | Rp408.92 Billion | Rp462.99 Billion | Rp477.15 Billion | Rp471.39 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Rp1.76 Trillion | Rp1.56 Trillion | Rp1.45 Trillion | Rp1.50 Trillion | Rp1.28 Trillion |
| Total Current Liabilities | Rp1.51 Trillion | Rp1.23 Trillion | Rp985.25 Billion | Rp1.05 Trillion | Rp836.75 Billion |
| Long-term Debt | Rp215.41 Billion | Rp295.65 Billion | Rp429.79 Billion | Rp394.52 Billion | Rp360.78 Billion |
| Net Debt | Rp728.86 Billion | Rp684.68 Billion | Rp357.46 Billion | Rp224.02 Billion | Rp299.31 Billion |
| Total Stockholder Equity | Rp-1.14 Trillion | Rp-804.13 Billion | Rp86.36 Billion | Rp508.30 Billion | Rp430.32 Billion |
| Retained Earnings | Rp-1.75 Trillion | Rp-1.41 Trillion | Rp-616.30 Billion | Rp-187.83 Billion | Rp-150.25 Billion |
Indofarma Tbk Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Indofarma Tbk generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rp-21.65 Billion | Rp-190.10 Billion | Rp-75.95 Billion | Rp92.90 Billion | Rp46.55 Billion |
| Capital Expenditures | Rp425.75 Million | Rp4.74 Billion | Rp13.48 Billion | Rp21.40 Billion | Rp13.78 Billion |
| Free Cash Flow | Rp-22.08 Billion | Rp-194.84 Billion | Rp-89.42 Billion | Rp71.50 Billion | Rp32.77 Billion |
| Investing Cash Flow | Rp-319.81 Million | Rp-4.68 Billion | Rp-13.40 Billion | Rp-114.41 Billion | Rp-9.04 Billion |
| Financing Cash Flow | Rp14.98 Billion | Rp-57.85 Billion | Rp13.33 Billion | Rp244.15 Billion | Rp-30.68 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | — | Rp27.64 Billion | Rp18.63 Billion | Rp34.60 Billion | Rp28.27 Billion |
| Change in Cash | Rp-6.96 Billion | Rp-252.68 Billion | Rp-76.06 Billion | Rp222.64 Billion | Rp6.79 Billion |
Indofarma Tbk Earnings History — EPS Actual vs. Analyst Estimates
Track Indofarma Tbk's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jul 29, 2025 | — | — | — |
| Aug 03, 2023 | -18.89 | — | — |
| May 02, 2023 | -19.94 | — | — |
| Dec 31, 2022 | -79.16 | — | — |
| Nov 23, 2022 | -29.81 | — | — |
| Aug 16, 2022 | -12.76 | — | — |
| Mar 31, 2022 | -16.51 | — | — |
| Dec 31, 2021 | -13.04 | — | — |